In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
New Gibco AAV-MAX Helper Free AAV Production System helps reduce production costs and streamline the transition from research to clinical environments
The CASPIAN Phase III trial in extensive-stage small-cell lung cancer is the longest survival follow-up ever reported for immunotherapy treatment in this setting
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
This award is open to all currently operational laboratories pertaining to testing, calibration & medical including their proficiency testing providers & reference material producers located in India
Barbara Engelhardt moves her computational and statistics lab to Gladstone
Data show the vaccine regimen induced neutralising antibody responses in nearly all participating adults and children 21 days after the second dose. Adults receiving booster shots two years after the initial vaccination regimen showed strong immune responses
This low-cost and highly reliable technology will help in increasing testing in rural and tribal areas
The study is being carried out by the platform VISION (Vaccine Immunology Studies – Indian Outbreak-response Network) which includes top public and private research institutes.
Union Minister addresses the 13th CII Global MedTech Summit on the sunrise medical devices sector in India
Subscribe To Our Newsletter & Stay Updated
